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A b s t r a c t
Introduction: CCL5/RANTES and IL-1β, which regulate the immune response, may have an impact on survival in patients with 
acute coronary syndrome (ACS) and sudden cardiac arrest (SCA).
Aim: To evaluate levels of CCL5/RANTES and IL-1β in patients with ACS complicated by SCA, treated with coronary angioplasty 
(PCI) and mild therapeutic hypothermia (MTH), and these chemokines’ impact on the 30- and 180-day survival. 
Material and methods: Thirty-three unconscious patients admitted after SCA with ACS underwent PCI and MTH treatment. 
CCL5/RANTES and IL-1β were evaluated on admission (T0), at 12–24 h (T1) and at 48–72 h (T2). All-cause mortality was recorded 
at 30 and 180 days.
Results: We observed a statistically significant decrease in median levels of CCL/RANTES at T0, T1 and T2 (24.69 ng/ml vs. 
3.89 ng/ml vs. 2.71 ng/ml; p < 0.001), and significant differences in median levels of IL-1β (0.196 pg/ml vs. 0.171 pg/ml vs. 0.214 pg/ml; 
p = 0.034). Initial levels of CCL5/RANTES and IL-1β correlated significantly (r = –0.360; p = 0.045). At T2, CCL5/RANTES correlated 
with the maximum levels of hs-TnT and CK-MB (r = –0.594; p < 0.001 and r = –0.389; p = 0.030), and at T0 with BNP (r = –0.521; 
p = 0.003). Mortality rate at 30 days and 180 days was 18.2% and 45.5%, respectively. At 30 days, we observed a trend to signif-
icance for IL-1β at T0 and T1 (p = 0.078 and p = 0.079), but not for CCL5/RANTES (p = 0.284 and p = 0.351). For 180-day survival 
curves, only the IL-1β level at T1 was associated with mortality (p = 0.028).
Conclusions: Although CCL5/RANTES levels correlate with cardiac injury and heart failure markers and they decrease during 
MTH, they failed to predict early and late mortality. In contrast, IL-1β level was associated with 180-day survival. 
Key words: chemokine RANTES, IL-1β, mild therapeutic hypothermia, sudden cardiac arrest.
S u m m a r y
Chemokine CCL5/RANTES is present in early stages of the inflammatory process in patients with out-of-hospital cardiac 
arrest, which then significantly decreases during mild therapeutic hypothermia. The MTH leads to a decrease in the inflamma-
tory response measured by IL-1β. The level of IL-1β measured during MTH was significantly associated with long-term all-cause 
mortality. CCL5/RANTES levels correlate with myocardial injury and BNP levels.
Introduction
The most common cause of sudden cardiac arrest 
(SCA) is acute coronary syndrome (ACS). In Poland, over 
177 000 patients died due to cardiac diseases in 2013, 
which accounted for 45.8% of all deaths [1]. Out-of-hos-
pital cardiac arrest (OHCA) is associated with a  partic-
ularly poor prognosis and low survival rates. Moreover, 
these patients are at risk for neurological damage [2, 3]. 
Post-resuscitation syndrome includes complex damage 
of individual organs caused by ischemia-reperfusion in-
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jury [4]. To protect against organ damage, mild therapeu-
tic hypothermia (MTH), which is defined as a controlled 
decrease in body temperature to 32–34°C [5, 6], was re-
cently introduced [7, 8]. 
An Australian study by Bernard et al. and a Europe-
an study by the Hypothermia after Cardiac Arrest (HACA) 
working group have documented that the use of thera-
peutic hypothermia was associated with clinically signifi-
cant neurological improvement and a 14% improvement 
in survival 6 months after resuscitation compared to the 
control group without hypothermia induction (59% vs. 
45%, p < 0.02) [5, 6]. The results of these studies have 
suggested that current guidelines of the European Re-
suscitation Council (ERC) and the European Society of 
Cardiology (ESC) recommend therapeutic hypothermia 
and/or (recently) target temperature management (TTM) 
in patients with OHCA, regardless of the rhythm which 
initiated sudden cardiac arrest [9].
However, it is controversial whether MTH might trig-
ger infectious complications through a pro-inflammatory 
effect (including sepsis) or by creating a “sepsis-like” syn-
drome via an increase in pro-inflammatory cytokines, in-
cluding interleukin (IL)-1β, IL-8, and tumor necrosis factor 
(TNF)-α [10]. A significant correlation has been demon-
strated between chemokine (C-C motif) ligand 5 (CCL5), 
also known as regulated on activation, normal T cell ex-
pressed and secreted (RANTES), IL-1β level, and mortality 
risk in patients with acute coronary syndromes [11–13]. 
Chemokine CCL5/RANTES level is a marker of coronary 
artery disease severity [14, 15]. An expanded panel of 
inflammatory parameters (CCL5/RANTES and IL-1β level) 
in association with basic measurements (C-reactive pro-
tein (CRP), leukocytes, neutrophils) during therapeutic 
hypothermia may have potential benefits, including pre-
vention of undesirable effects, for optimization of anti-in-
flammatory therapy or predicting prognosis in patients 
with ACS complicated by SCA undergoing percutaneous 
coronary interventions.
Aim
The aim of the study was to evaluate the activity of 
chemokines which regulate immune cell vascular chemo-
taxis, including CCL5/RANTES and IL-1β, and their poten-
tial impact on 30-day and 180-day prognosis in patients 
with ACS complicated by SCA treated with coronary an-
gioplasty and MTH.
Material and methods
The study included 33 unconscious patients (27 male, 
mean age: 66.1 ±10.8 years) admitted after out-of-hos-
pital cardiac arrest as a result of ACS between July 2011 
and June 2016. Inclusion criteria were as follows: ACS 
complicated by OHCA with return of spontaneous circula-
tion (ROSC) and treated using MTH. Patients needed to be 
> 18 years of age and underwent percutaneous coronary 
intervention (PCI) of a culprit artery with implantation of 
a coronary stent. Patients were excluded from MTH if they 
had a known coagulopathy or active bleeding. All patients 
had MTH induction in accordance with European Society 
of Cardiology guidelines [16]. Written informed consent 
was obtained from patients after regaining consciousness 
following cardiac arrest. The Jagiellonian University Ethics 
Committee in Krakow approved the protocol.
Cardiac revascularization and patient 
management
All patients underwent early PCI and received opti-
mal medical treatment according to current guidelines 
[17]. Each patient received periprocedural unfractionated 
heparin intravenously according to weight and dual anti-
platelet therapy via a nasogastric tube. During the proce-
dure, GP IIb/IIIa was administered at the discretion of the 
interventional cardiologist. A drug-eluting stent was im-
planted in 26 (78.8%) patients, while a bare metal stent 
was implanted in 4 (12.1) patients. Balloon angioplasty 
without stent implantation was performed in 2 (6.1%) 
patients, while in 1 patient, balloon introduction was un-
successful. SYNTAX score, as well as TIMI scales (pre- and 
post-PCI), were assessed in all subjects. 
Inflammatory biomarkers
Blood samples were drawn from an antecubital vein 
on admission (T0), at 12–24 h (T1), and 48–72 h (T2) after 
PCI and placed in a collection tube. Plasma was centri-
fuged for 15 min at 1600 x g at 4°C. Collected serum 
aliquots were immediately stored at ≤ –70°C for further 
analysis of CCL5/RANTES and IL-1β. Biomarker serum 
levels were determined by ELISA (Human CCL5/RANTES 
Immunoassay no. DRN00B, Human IL1β1 Immunoassay 
R&D systems, Minneapolis, MN, USA) following the man-
ufacturer’s instructions.
Blood sampling
Baseline blood samples, including biochemical tests, 
CRP, BNP, coagulation, blood gas analysis, and myocardial 
injury markers were taken on admission to the hospital 
(T
0
), and then at T
1
 (12–24 h) and T
2 
(48–72 h). Average 
core temperatures were as follows: at T
0
 35.4 ±0.6°C; at 
T
1
 32.4 ±0.5°C; and at T
2
 36.6 ±0.4°C.
Mild therapeutic hypothermia protocol
To induce hypothermia, infusion of cold saline (NaCl 
0.9% at 4°C) was initiated during PCI. After PCI and 
transportation to the intensive care unit, therapeutic hy-
pothermia was achieved through the use of an endovas-
cular cooling device (Coolgard, Zoll Medical Corporation 
Chelmsford, MA, USA). According to the protocol, cooling 
was maintained for 24 h with a  target temperature of 
33°C. After reaching the target temperature, rewarming 
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was performed at a  rate of 0.2°C/h. All patients during 
MTH received intravenous injection of an analgesic opi-
oid and a  sedation drug. Additionally, neuromuscular 
blockade (NMB) was often used in accordance with the 
protocol of MTH.
Patient discharge and follow-up 
The primary endpoint was to establish the pattern of 
CCL5/RANTES and IL-1β changes at 3 time points, and to 
determine correlations between CCL5/RANTES and IL-1β 
along with inflammatory, coagulation, and myocardial in-
jury/heart failure biomarkers.
The secondary endpoint was to analyze the relation-
ship between CCL5/RANTES, IL-1β, and the 30-day and 
180-day mortality. Neurological outcome was assessed 
at discharge according to the Pittsburgh Cerebral Perfor-
mance Category (CPC) [18, 19]. CPC scores 1 and 2 were 
defined as favorable neurological outcomes, whereas 
CPC scores 3, 4, and 5 were associated with a poor neu-
rological outcome. 
Statistical analysis
The data are presented as mean with standard devi-
ations or medians with interquartile range. Continuous 
variables were compared with Student’s t-test for nor-
mally distributed variables or with the non-parametric 
Mann-Whitney U  test for non-normally distributed vari-
ables. The χ2 test was used to compare proportions of cate-
gorical variables. Means of the analyzed parameters across 
groups were tested by analysis of variance (ANOVA). 
Correlations were assessed by the Pearson correla-
tion test or by Spearman’s rank test. Survival analysis 
Variables MTH* (n = 33)
Age [years] 66.1 ±10.8
Male sex, n (%) 27 (81.8%)
Systolic blood pressure [mm Hg] 120 (102–147)
Diastolic blood pressure [mm Hg] 80 (65–91)
History of hypertension 25 (75.8%)
Diabetes mellitus 11 (33.3%)
Hypercholesterolemia 20 (60.6%)
Obesity 13 (39.4%)
Active smoker 10 (30.3%)
Prior myocardial infarction 8 (24.2%)
Prior PCI 2 (6.1%)
Prior CABG 2 (6.1%) 
Prior stroke 5 (15.2%)
Circumstances of sudden cardiac arrest:
Ventricular tachycardia/ventricular fibrillation 28 (84.8%)
Asystole 3 (9.1%)
Pulseless electrical activity 2 (6.1%)
Basic life support/advanced life support 23 (69.7%)
Time to return of spontaneous circulation [min] 23 ±16
Preserved pupillary reflex 23 (69.7%)
Glasgow Coma Scale ≤ 4 21 (63.6%)
Glasgow Coma Scale > 4 12 (36.4%)
Clinical state at admission to hospital
Cardiogenic shock at admission 8 (24.2%)
STEMI 20 (60.6%)
Course of hospitalization:
Time from cardiac arrest to PCI [min] 122.1 (60.1)
Acute coronary occlusion 16 (48.5%)
Extent of coronary artery disease:
1-vessel 14 (42.4%)
2-vessel 10 (30.3%)
3-vessel 9 (27.3%)
Variables MTH* (n = 33)
Left main stenosis 1 (3.0%)
SYNTAX score 20 (6.5–29.5)
Surgical revascularization 0
Bare-metal stents used 4 (12.1%)
Drug-eluting stents used 26 (78.8%)
Only balloon angioplasty 2 (6.1%)
Failed PCI 1 (3.0%)
TIMI flow pre-PCI:
0 18 (54.5%)
1 1 (3.0%)
2 2 (6.0%)
3 12 (36.4%)
TIMI flow post-PCI:
0 3 (9.1%)
1 1 (3.0%)
2 0 (0.0%)
3 29 (87.9%)
Thienopyridine use:
Clopidogrel 12 (36.4%)
Ticagrelor 21 (63.6%)
Cardiogenic shock (after admission) 17 (51.5%)
Intra-aortic balloon counterpulsation 0 3 (9.1%)
Left ventricular ejection fraction max. 44 (14.8%)
Pneumonia 24 (72.7%)
Blood transfusion 12 (36.4%)
Renal failure 23 (69.7%)
Stroke 6 (18.2%)
Sepsis 4 (12.1%)
30-day mortality 6 (18.2%)
180-day mortality 15 (45.5%)
30-day favorable neurological outcome (CPC 1-2) 16 (48.5%)
180-day favorable neurological outcome (CPC 1-2) 17 (51.5%)
Table I. Characteristics of patients undergoing mild therapeutic hypothermia (MTH)
*Mild therapeutic hypothermia; PCI – percutaneous coronary intervention, CABG – coronary artery bypass grafting, STEMI – ST-elevation myocardial infarction, 
TIMI – thrombolysis in myocardial infarction, CPC – cerebral performance category.
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was performed using Kaplan-Meier curves followed by 
the log-rank test. All analyses were performed using IBM 
SPSS Statistics and Statistica 13.0 software. P-values of 
< 0.05 were considered statistically significant.
Results
Baseline characteristics of study participants are 
shown in Table I. The all-cause mortality among study 
participants at 30-day and 180-day follow-up was 18.2% 
and 45.5% respectively. Sixteen (48.5%) out of the 33 
patients had a favorable neurologic outcome at the 30-
day observation. At the end of the follow-up period, 
17 (51.5%) patients had a favorable neurologic outcome. 
Laboratory findings on admission, during, and after MTH 
are summarized in Table II.
There were significant differences in median serum lev-
els of RANTES as well as IL-1β measured at T0, T1, and T2: 
24.69 (Q1:Q3: 11.8–37.5) ng/ml vs. 3.89 (Q1:Q3: 2.6–7.9) 
ng/ml vs. 2.71 (Q1:Q3: 2.0–5.5) ng/ml; p < 0.001 and 0.196 
(Q1:Q3: 0.12–0.38) pg/ml vs. 0.171 (0.07–0.31) pg/ml 
Table II. Standard laboratory, coagulation parameters, peripheral blood gas analysis, myocardial injury markers 
and immune system parameters on admission (T0) during mild therapeutic hypothermia (MTH) (12–24 h; T1) 
and during rewarming after MTH (48–72 h; T2)
Variables T0 T1 T2
WBC [× 10–3/µl] 14.6 ±5.9 12.1 ±4.4 12.3 ±4.5
RBC [× 10–6/µl] 4.6 ±0.5 4.1 ±0.5 3.7 ±0.5
Hb [g/dl] 13.9 ±1.5 12.5 ±1.6 11.1 ±1.3
PLT [× 10–3/µl] 187.8 ±49.5 150.4 ±42.4 134.2 ±46.4
Creatinine [µmol/l] 127.5 ±89.3 104.1 ±109.1 119.7 ±87.6
GFR 56.8 ±18.0 77.2 ±27.4 66.7 ±27.7
BNP [pg/ml] 2596.1 ±7532.5 3690.5 ±7009.3 5994.0 ±8054.0 
Amylase [U/l] 99.9 ±71.0 232.3 ±266.3 158.9 ±140.8
ALT [U/l] 130.9 ±141.1 121.2 ±108.4 78.5 ±45.4
AST [U/l] 139.2 ±121.2 227.0 ±222.3 124.3 ±80.3
Bilirubin [µmol/l] 8.6 ±3.7 9.0 ±4.8 8.6 ±5.6
ALP [U/l] 91.7 ±42.6 68.3 ±36.6 71.5 ±28.3
CRP [mg/l] 3.3 ±4.7 27.4 ±18.5 165.6 ±74.3
Coagulation parameters:
INR 1.2 ±0.5 1.2 ±0.5 1.2 ±0.4
DD [µg/l] 15453.2 ±13702.7 2631.9 ±2696.4 1232.5 ±1103.1
Fibrinogen [g/l] 3.0 ±0.8 3.1 ±0.9 5.0 ±1.2
Peripheral blood gas analysis:
pCO
2
 [mm Hg] 40.7 ±7.3 40.3 ±7.4 39.6 ±8.4
pO
2
 [mm Hg] 223.1 ±102.9 145.9 ±35.3 116.5 ±30
pH value 7.28 ±0.10 7.30 ±0.08 7.38 ±0.07
Lactate [mmol/l] 5.0 ±2.9 2.5 ±2.2 1.4 ±0.7
Myocardial injury markers:
hs-TnT [ng/ml] 0.217 ±0.170 1.992 ±2.895 1.524 ±2.276
CK-MB [U/l] 77.0 ±47.2 267.0 ±271.2 106.0 ±98.1
CK [U/l] 381.3 ±340.6 3307.8 ±3101.2 2717.7 ±2133.2
ALP – alkaline phosphatase, ALT – alanine transaminase, AST – aspartate transaminase, BNP – B-type natriuretic peptide, CK – creatine kinase, CK-MB – creatine 
kinase-MB (CK-MB), CRP – C reactive protein, DD – D-dimer, GFR – glomerular filtration rate, INR – international normalized ratio, Hb – hemoglobin, hs-TnT – 
high-sensitivity troponin T, pCO
2
 – partial pressure of carbon dioxide, pO
2
 – partial pressure of oxygen, PLT – platelets, RBC – red blood cell, WBC – white blood cells.
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vs. 0.214 (Q1:Q3: 0.15–0.41) pg/ml; p = 0.034, respec-
tively (Figures 1 A, B).
A statistically significant correlation was observed be-
tween CCL5/RANTES and IL-1β levels at T0 (r = –0.360; 
p = 0.045) (Figure 2 A), while there was no statistically 
significant correlation between these cytokines at T1 and 
T2 (r = –0.208; p = 0.252 and r = –0.139; p = 0.473, re-
spectively). 
CCL5/RANTES level correlated significantly with brain 
natriuretic protein (BNP) value at T0 (r = –0.521; p = 
0.003) (Figure 2 B), while an inverse correlation was ob-
served for IL-1β at T1 and BNP level at T1 (r = 0.478; p = 
0.008) (Figure 2 C). IL-1β also correlated with fibrinogen 
level at T1 (r = –0446; p = 0.012) (Figure 2 D). 
There was a  significant correlation between IL-1β 
and SYNTAX score at T1 (r = 0.378; p = 0.033), whereas 
no correlation between CCL5/RANTES level and SYNTAX 
score was observed.
Maximum high-sensitivity troponin and CK-MB levels 
negatively correlated with CCL5/RANTES level at T2 (r = 
–0.594; p < 0.001 and r = –0.389; p = 0.030, respectively), 
but not with IL-1β (Figures 3 A, B).
Kaplan-Meier survival curves for medians of CCL5/
RANTES and IL-1β levels at T0 and T1 were calculated for 
30-day and 180-day mortality. 
For 30-day survival curves, the levels of IL-1β at T0 
and T1 showed a  trend to significance with all-cause 
mortality rate (p = 0.078; p = 0.079, respectively) (Fig- 
ure 4 A  a, b). Levels of CCL5/RANTES at T0 and T1 did 
not have an influence on 30-day mortality (p = 0.284; 
p = 0.351, respectively) (Figure 4 A c, d). 
For 180-day survival curves, the level of IL-1β at T1 
significantly associated with all-cause mortality (p = 
0.028) (Figure 4 B a), whereas IL-1β level at T0 as well as 
CCL5/RANTES levels at T0 and T1 did not show a statisti-
cally significant association with 180-day mortality (p = 
0.391; p = 0.758; p = 0.502, respectively) (Figure 4 B b–d).
Discussion
To our knowledge, this is the first prospective study 
investigating chemokines which regulate immune cell 
vascular chemotaxis, including CCL5/RANTES and IL-1β, 
in MTH in patients with cardiac arrest due to ACS treated 
with PCI. 
The main finding of our study is that there are import-
ant differences in levels of CCL5/RANTES and IL-1β with 
regard to time frames. We observed a clear and steady 
decrease in CCL5/RANTES levels from T0 to T2. This sup-
ports the relationship of a chemokine CCL5/RANTES early 
increase which typically accompanies activation of an in-
travascular inflammatory response [20].
CCL5/RANTES is mainly produced by T cells, endothe-
lial cells, platelets, and smooth muscle cells and stimu-
lates leukocytes to migrate into inflammatory tissue or 
into the wall of an injured artery [21]. When released 
from activated platelets, CCL5/RANTES triggers mono-
cyte migration and arrest to the endothelium in the in-
flamed or atherosclerotic area [22], and has a significant 
effect on atherosclerotic lesion size and plaque develop-
ment. Furthermore, CCL5/RANTES has a  role in plaque 
destabilization and remodeling [23].
In this context, our results suggest that MTH leads 
to a rapid reduction in CCL5/RANTES levels, which might 
have a beneficial effect on decreasing the inflammato-
ry response. The same effect was observed for IL-1β 
during MTH. However, the effect of CCL5/RANTES reduc-
tion remained even after patient rewarming, whereas 
IL-1β levels decreased at T1 and then increased after 
rewarming of the patient. This might mimic the so-
Figure 1. Serum RANTES and IL-1β levels at T0, T1, and T2
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Figure 2. Correlations of RANTES and IL-1β cytokines with regard to laboratory parameters
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Figure 4. A – Kaplan-Meier curves for 30-day mortality stratified according to median levels of IL-1β at T0 (a) 
and T1 (b) and RANTES at T0 (c) and T1 (d)
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called sepsis-like syndrome, along with an increase in 
CRP levels, but not in white blood cell count. In line with 
our findings, MTH was associated with a  reduction in 
immune cell infiltration, apoptosis, IL-1β, and IL-6. Hy-
pothermia reduced myocardial damage and dysfunction 
after cardiopulmonary resuscitation, possibly via a  re-
duced rate of apoptosis and pro-inflammatory cytokine 
expression [24]. 
Of note, it was previously shown that other inflam-
matory markers including cytokine IL-6 and procalcitonin 
levels in patients treated with MTH were associated with 
higher mortality rates measured 24 h after out-of-hos-
pital SCA [25, 26]. The CRP levels on admission were 
associated with poorer outcomes in a  similar group of 
patients [27]. Our data support these findings, as IL-1β 
levels were associated with 180-day mortality.
Cavusoglu et al. [28] reported that low baseline CCL5/
RANTES levels were an independent predictor of cardiac 
mortality, with a survival rate of 87.3% in the lowest ter-
tile of CCL5/RANTES values, compared with 94% in the 
upper 1st and 2nd tertile (p = 0.0298 by log-rank test) in 
patients referred for coronary angiography [14, 18, 29].
Lipkova et al. observed decreased serum CCL5/
RANTES levels in ACS patients, which were associated 
with the severity of myocardial infarction and progres-
sion, with the lowest levels seen in cardiogenic shock pa-
tients (cutoff level ≥ 80.4 ng/ml). This strongly suggests 
a role for CCL5/RANTES as a potential biomarker of car-
diogenic shock and acute heart failure in the post-ACS 
hospitalization phase [30]. 
In ACS patients with induced MTH, CCL5/RANTES lev-
els did not correlate with 30-day or 180-day mortality. 
This might be reflected by the fact that the CCL5/RANTES 
impact on mortality was diminished by a decreased in-
flammatory process and prohibition of further cardiac 
remodeling. Of note, CCL5/RANTES levels correlated with 
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Figure 4. Cont. B – Kaplan-Meier curves for 180-day mortality stratified according to median levels of IL-1β at 
T0 (a) and T1 (b) and RANTES at T0 (c) and T1 (d)
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cardiac injury and heart failure markers, which still make 
them potentially valuable, provoking the need for further 
investigation.
Taken together, this suggests a potentially important 
role for CCL5/RANTES and IL-1β in patients with ACS and 
cardiogenic shock. All of the above-mentioned biomark-
ers correlate with post-MI survival and have an impact on 
short- and long-term survival [31]. 
Study limitations
The study group was relatively small and no control 
group was used due to ethical reasons and the critical 
status of all patients. However, the overall group size was 
sufficient to detect correlations. We assessed cytokine 
levels only via serum gene expression and not through 
left ventricular tissue gene expression. 
Conclusions
The chemokine CCL5/RANTES is present in early stag-
es of the inflammatory process in out-of-hospital car-
diac arrest patients, then significantly decreases during 
MTH. The MTH leads to a decrease in the inflammatory 
response as measured by IL-1β. The level of IL-1β mea-
sured during MTH was significantly associated with long-
term all-cause mortality. CCL5/RANTES levels correlated 
with myocardial injury and BNP levels.
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